Takase H, Murakami Y, Endo A, Ikeuchi T
New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan.
Vaccine. 1996 Dec;14(17-18):1651-6. doi: 10.1016/s0264-410x(96)00128-4.
Antibody responses and protection were studied in BALB/c mice immunized orally with formalin-inactivated influenza viruses (A/PR/8/34) combined with cholera toxin B subunit as adjuvant. Influenza virus-specific IgA as well as IgG antibody responses were induced in the mice, depending on the oral dosage frequency. The oral immunization by multiple doses resulted in reduction of viral replication in the nose and prevention of development of infection in the lung after intranasal (i.n.) challenge. The protective effect in the nose was thought to be related to the nasal IgA antibody response. The oral immunization was, however, less efficient for induction of the IgA antibody response and protection in the nose, compared with an i.n. immunization. The oral immunization following subcutaneous priming led to the complete protection in the nose, accompanied-by a prompt local IgA antibody response.
在以霍乱毒素B亚基作为佐剂,经口服福尔马林灭活流感病毒(A/PR/8/34)免疫的BALB/c小鼠中研究了抗体反应和保护作用。根据口服剂量频率,小鼠体内诱导出了流感病毒特异性IgA以及IgG抗体反应。多剂量口服免疫可减少鼻腔中的病毒复制,并预防鼻内(i.n.)攻击后肺部感染的发生。鼻腔中的保护作用被认为与鼻内IgA抗体反应有关。然而,与鼻内免疫相比,口服免疫诱导鼻内IgA抗体反应和保护的效率较低。皮下预免疫后进行口服免疫可导致鼻腔完全得到保护,并伴有迅速的局部IgA抗体反应。